SynthesisWorld journal of gastroenterology2021
Minimum sample size estimates for trials in inflammatory bowel disease: A systematic review of a support resource.
Synthesis in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 9 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years.Journal of pediatric gastroenterology and nutrition · 2026Guideline
- Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis.BMJ open gastroenterology · 2026Pooled it
- Efficacy and safety of non-pharmacological treatments for paediatric functional constipation: a systematic review and meta-analysis.BMJ paediatrics open · 2026Pooled it
- Prebiotics for induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2024Pooled it
- Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review.BMJ open gastroenterology · 2024Pooled it
- Infliximab for maintenance of medically-induced remission in Crohn's disease.The Cochrane database of systematic reviews · 2024Pooled it
- Infliximab for medical induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2023Pooled it
- Vitamin D for the treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- Vedolizumab for induction and maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2023Pooled it
- Article
- Revolutionizing IBD Clinical Trials with Bayesian Approaches.Inflammatory bowel diseases · 2025Article
- Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions.Inflammatory bowel diseases · 2025Article
- Article
- ESPGHAN and NASPGHAN 2024 protocol for paediatric functional constipation treatment guidelines (standard operating procedure).BMJ paediatrics open · 2025Article
- Navigating the complexities of drug development for inflammatory bowel disease.Nature reviews. Drug discovery · 2024Review
- Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study.EClinicalMedicine · 2023Article
- Medical treatment of eosinophilic esophagitis.The Cochrane database of systematic reviews · 2023Review
- Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOf 25% of randomised controlled trials (RCTs) on interventions for inflammatory bowel disease (IBD) have no power calculation.
aimTo systematically review RCTs reporting interventions for the management of IBD and to produce data for minimum sample sizes that would achieve appropriate power using the actual clinical data.
methodsWe included RCTs retrieved from Cochrane IBD specialised Trial register and CENTRAL investigating any form of therapy for either induction or maintenance of remission against control, placebo, or no intervention of IBD in patients of any age. The relevant data was extracted, and the studies were grouped according to the intervention used. We recalculated sample size and the achieved difference, as well as minimum sample sizes needed in the future.
resultsA total of 105 trials were included. There was a large discrepancy between the estimated figure for the minimal clinically important difference used for the calculations (15% group differences observed
conclusionA third of intervention studies in IBD within the last 25 years are underpowered, with large variations in the calculation of sample sizes. The authors present a sample size estimate resource constructed on the published evidence base for future researchers and key stakeholders within the IBD trial field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.